Target intelligence / Profile preview

Inhibin subunit beta E mRNA (INHBE mRNA)

Target
INHBE mRNA
Molecular classification
Other, mRNA
01

Overview

Inhibin subunit beta E (INHBE) mRNA is the transcript encoding the hepatokine Activin E, a member of the transforming growth factor-beta (TGF-beta) superfamily. Synthesized primarily in the liver, Activin E is secreted into circulation and acts on ALK7 (ACVR1C) receptors on adipocytes to suppress lipolysis and promote lipid storage, thereby regulating energy homeostasis and fat distribution. Human genetic studies have shown that individuals carrying naturally occurring loss-of-function variants in the INHBE gene exhibit a healthier metabolic profile, characterized by reduced visceral fat, lower triglyceride levels, and a decreased risk of type 2 diabetes and cardiovascular disease. Consequently, INHBE mRNA has emerged as a highly promising therapeutic target for the treatment of obesity and metabolic disorders.

Therapeutic strategies targeting INHBE mRNA primarily utilize RNA interference (RNAi) to selectively silence the gene in hepatocytes. Investigational small interfering RNA (siRNA) drugs, such as WVE-007, ARO-INHBE, CMS-D008, SRSD384, RBD3133, IBI3046, and RN3161, are designed to bind to and degrade INHBE mRNA. This knockdown reduces circulating Activin E levels, disinhibiting lipolysis and promoting fat-specific weight loss while preserving lean muscle mass. This muscle-sparing profile represents a significant advantage over traditional GLP-1 receptor agonists, which are often associated with muscle loss. Clinical trials are currently evaluating these siRNA candidates both as monotherapies and in combination with incretin-based therapies to achieve synergistic and durable metabolic improvements.

Other names
Inhibin beta E mRNAInhibin subunit beta E transcriptActivin beta-E chain mRNAActivin beta E subunit mRNAINHBE transcriptINHBE mRNA
02

Mechanism of action

Small interfering RNA (siRNA) mediated gene silencing leading to mRNA degradation and reduction of hepatic INHBE expression

03

Biological functions

Signal transductionOther
04

Disease associations

Cardiovascular diseaseOther
05

Safety considerations

Injection site reactionsPotential off-target effects of siRNALong-term safety of systemic Activin E suppressionGastrointestinal adverse events when combined with GLP-1 receptor agonists
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Activin EINHBE mRNABody weightBody compositionVisceral fatLiver fatTriglyceridesInsulin sensitivity

Beyond the preview

Go deeper on Inhibin subunit beta E mRNA (INHBE mRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibin subunit beta E mRNA (INHBE mRNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call